

impress

strives for the implementation of a simple-to-use, reliable system for non-invasive continuous blood pressure measurement as a new clinical standard: Patients will be spared pain and the risk of complication while health care providers will be able to better monitor their patient's status and thus improve patient outcomes and save costs.

Technology

- 20% of all surgeries, or more than 50 million, per year worldwide – from Cesarean section to hip replacements – require continuous blood pressure monitoring. Until today, no non-invasive method exists that is suitable for clinical practice, thus making monitoring this vital sign unnecessarily painful, risky, time-consuming, and expensive.
- impress provides continuous non-invasive blood pressure measurement utilizing a cheap, robust, and clinically well-known setup. impress ties easily into existing multi-parameter monitoring equipment and requires practically no instrumentation training, thus allowing for fast acceptance as the clinical standard.
- impress technology is patented in Europe (PCT/EP2010/062873), with applications in US and Japan.

Market

- The global market for non-invasive, continuous blood pressure measurement devices in 2013 is estimated at € 1.3bn.
- Disposable electrodes represent substantial potential.
- impress builds its GTM strategy around clinical application areas with high potential and considerable size, geographically in Europe and markets with high demand, to enhance health care and to face challenges where non-invasive methods are preferable and where reasonable market entrance hurdles exist.

Products

Products	Application	Stage of development
– Impress BP Monitor	Non-invasive continuous clinical blood pressure monitoring	Class IIb, under development



impress Team: Arnulf Heller (center left), Christopher Arbeiter (center right), Eva Grieshaber, Bernd Höfler



Company Profile

Founded: 2013
Legal Form: e.U.
Employees: 1

Management Team

CEO: Arnulf Heller
Christopher Arbeiter
Eva Grieshaber
Bernd Höfler
Martin Götting (fundraising)

Public Funding

aws PreSeed: € 200,000
FFG Basis: € 170,000



Impress MedTech e.U.

Plüddemanngasse 39
8010 Graz, Styria, Austria
+43 664 5411121
arnulf.heller@smartnibp.com